| Date | Title | Description |
| 03.05.2024 | Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost | Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI... |
| 02.05.2024 | Karius Raises $100M in Series C Funding | Karius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding.
The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n... |
| 02.05.2024 | Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test | What You Should Know:
– Karius®, a leader in genomic diagnostics for infectious disease, announced today the closing of a $100 million Series C funding round.
– Co-led by Khosla Ventures and newcomers 5AM Ventures and Gilde Healthcare, the ... |
| 24.05.2023 | AbCellera receives $300 million in combined government funding for biotech campus | - |
| 08.11.2022 | “It’s not just about work.” – How (and why) to get a job at AbCellera | The How to get a job story series is supported by VanHack. Hire from VanHack’s 400K+ diverse tech talent pool, fast.
AbCellera’s chief commercial officer, Neil Aubuchon. Photo: supplied.
It’s safe to say that AbCellera is one of Vancouver’s... |
| 11.08.2022 | AbCellera Partners With Atlas Venture to Discover Therapeutic Antibodies | Vancouver, BC-based AbCellera (Nasdaq: ABCL) and Atlas Venture, a Cambridge, MA-based biotech venture capital firm, announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed a... |
| 10.08.2022 | Vancouver tech layoffs, talent, and hiring companies | As the innovation economy comes under pressure, a number of local tech companies have been forced to lay off employees. Here we’re sharing details on who has let go of staff, how to reach newly-available tech talent, and which companies are... |
| 15.12.2021 | Opinion: BC tech sector will roar even louder in 2022 | There’s no such thing as too much of a good thing. A case in point: The stellar year BC’s tech sector has had.
A record-setting 14 companies achieved valuations of $1 billion or more via IPOs, financing and acquisitions, with the Canadian V... |
| 06.12.2021 | AbCellera’s antibody treatment becomes first to receive emergency FDA approval for kids under 12 | Bamlanivimab, the antibody therapy discovered by Vancouver-based artificial intelligence (AI) biotech company AbCellera, has been granted emergency approval by the United States (US) to treat children with COVID-19.
On December 3, AbCellera... |
| 10.11.2021 | Ligand Pharma antibody spinoff plan sets up competition with AbCellera, Adimab | Antibodies are part of the wave of new biological drugs that are bringing new treatment options for patients and blockbuster sales for companies. As a growing number of biopharma companies look to beef up their antibody discovery capabiliti... |
| 24.09.2021 | Cheatsheet: 69 BC firms make Globe and Mail’s top growing companies list | Two weeks ago Ravi Kahlon, BC’s minister of jobs, economic recovery and innovation, celebrated the August Labour Force Results. He had good reason to. In August, BC had added 14,400 full-time jobs, with 13,600 of them going to women.
“B.C. ... |
| 23.09.2021 | AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies | VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and l... |
| 15.09.2021 | AbCellera Biologics : Acquisition expands AbCellera's existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs (Form 8-K) | Acquisition expands AbCellera's existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs
VANCOUVER, British Columbia & BOSTON, September 13, 2021 - AbCellera (Nasdaq: ABCL), a technology c... |
| 29.04.2021 | AbCellera breaks ground on new Vancouver HQ as it plans to hire hundreds | AbCellera, Canada’s most valuable biotech company, has broken ground on a new 380,000-square foot tech hub in Vancouver that is set to serve as the company’s new headquarters.
The hub comes in ahead of the Vancouver company’s plans to add “... |
| 01.04.2021 | ‘It is very personal’: AbCellera’s COVID-19 treatment is saving lives in the U.S. In Canada, it’s sitting in storage. Now the company’s CEO is speaking out | Article content
VANCOUVER — In early December, Kush Dalal answered a phone call from his 83-year-old father, then in a B.C. hospital battling COVID-19. Though coronavirus-related delirium had wreaked havoc in his brain, Dalal’s dad remember... |
| 23.03.2021 | Top 10 Medical Technology (MedTech) startups in Canada | Medical technology (MedTech), an industry that combines the power of technology with the capabilities of modern medical practices, is a sector that can by no means be overlooked in the world today. From the simple stethoscope to highly adva... |
| 03.03.2021 | International VC firm Presight Capital raises $350M second fund | Presight Capital has closed its $350 million second fund only a year and a half after it announced an $80 million first fund. In fact, General Partner Christian Angermayer told me that the fund was raised in just a few weeks, and that it sh... |
| 16.12.2020 | AbCellera officially closes initial public offering with $555.5 million gross proceeds | Vancouver biotech company AbCellera Biologics has officially announced the close of its initial public offering (IPO) on the Nasdaq, pulling in gross proceeds of $555.5 million.
The amount includes the company’s underwriters exercising in f... |
| 07.12.2020 | Thiel-backed therapy developer AbCellera looks to raise up to US$391 million in IPO | REUTERS: Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, said on Monday it expects to raise up to US$391 million in its initial public offering (IPO).
AbCeller... |
| 19.11.2020 | Peter Thiel Joins Board of Directors of AbCellera | AbCellera, a Vancouver, British Columbia, Canada-based technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, appointed Peter Thiel to its Board ... |
| 18.11.2020 | AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million | - |
| 30.09.2020 | Great 8: The top Vancouver VC-backed digital health companies right now | Back in May, a local tech investor told me that COVID had enabled digital health to take a great leap forward. “I would say we’ve moved more in two months than probably in the last four to five years,” he explained. He’s not the only person... |
| 27.05.2020 | Antibody drug tech firm AbCellera raises $105 million as it works on COVID-19 | By Jane Lanhee Lee
Canadian drug discovery technology company AbCellera, which analyzes and identifies antibodies for pharmaceutical companies working on a coronavirus treatment and other medicines, said on Wednesday it had raised $105 mill... |
| 27.05.2020 | AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform | - |
| 27.05.2020 | AbCellera secures $144 million CAD Series B funding round | Vancouver-based AbCellera has closed a $144 million CAD ($105 million USD) Series B funding round to help further advance its antibody drug discovery platform.
The round was led by OrbiMed, a United States-based healthcare-focused fund, and... |
| 27.05.2020 | Eli Lilly’s COVID-19 therapy development partner AbCellera raises $105 million | When AbCellera won a $30 million contract with the Defense Advanced Research Projects Agency to develop therapeutic countermeasures against viral outbreaks two years ago, it’s safe to assume that no one thought the technology would be so vi... |
| 03.05.2020 | AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs | - |
| 15.03.2020 | The Sunday Briefing | #96 | The Vancouver Tech Journal brings you news, insight, opinions, and the lesser-known stories from Vancouver's innovation ecosystem. This is The Sunday Briefing. Enjoy.
32 things learned about Shopify and their massive Vancouver expansion. Th... |
| 24.02.2020 | Invetx Announces $15 million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development | Anterra Capital leads financing to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma |
| 28.02.2019 | Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision | Alison Lawton
→ Kaleido Biosciences has raised $75 million to develop its microbiome metabolic therapies in a downsized IPO. The final going price for the 5,000,000 shares was $15 each, falling short of the $20-$22 range C... |
| 27.09.2018 | AbCellera raises $10M for machine-learning fueled antibody discovery platform | AbCellera co-founder Véronique Lecault, who joined the company’s board of directors Thursday. (AbCellera Photo)
AbCellera, a biotech startup based in Vancouver, B.C., announced Thursday that it has raised a $10 million series A round to exp... |
| 27.09.2018 | AbCellera Closes $10M Series A Financing | AbCellera, a Vancouver, BC, Canada-based developer of next-generation therapeutic antibodies, closed its $10m Series A financing.
The round was led by DCVC Bio. In connection with the investment, John Hamer, Managing Partner at DCVC Bio, jo... |
| - | Schrödinger: инвестиции в drug discovery и materials science. Есть ли перспективы после падения акций на 70%? | Для инвесторов в биотех и фармацевтические компании последний год выдался непростым. Популярный ETF SPDR S&P Biotech, он же XBI, состоящий в основном из биотехов малой и средней капитализации, потерял уже более 40% с пиковых значений в ... |
| - | Ligand Pharma antibody spinoff plan sets up competition with AbCellera, Adimab | Antibodies are part of the wave of new biological drugs that are bringing new treatment options for patients and blockbuster sales for companies. As a growing number of biopharma companies look to beef up their antibody discovery capabiliti... |
| - | adMare Launches Abdera with AbCellera as a Founding Partner | adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company developing novel ne... |
| - | Bulletin: Despite domestic snubbing, AbCellera made nearly $200 million off of its COVID-19 treatment | Vancouver’s AbCellera closed out a monster year in which it became Canada’s most valuable biotech company by growing year-over-year revenue 1,908% to $233 million USD.
The company announced Tuesday (March 29) that it generated a net profit ... |
